BMN-255

N/A

Report date: 2024/06/12 20:00:37
NME

Base Information

Drug NameBMN-255
Drug Alias NameBMN-255BMN 255
ClassificationSmall molecules
Mechanisms of ActionGlycolate oxidase inhibitors
TargetsGlycolate oxidase
Therapy Area/IndicationsKidney CalculiHyperoxaluriaMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiomarin Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiomarin Pharmaceutical Inc
Active IndicationsN/A
Inactive IndicationsKidney CalculiHyperoxaluriaMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A